TRANSCODE THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
TRANSCODE THERAPEUTICS, INC. (RNAZ) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1108.80 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-04-15
- TRANSCODE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $2.31.
- TRANSCODE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1108.80, a 85.19% decline from fiscal 2023.
- TRANSCODE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $7487.04, a 667.11% increase from fiscal 2022.
- TRANSCODE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $976.00, a 24861.64% increase from fiscal 2021.
- TRANSCODE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $3.91, a 1464.00% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $1108.80 10-K · filed 2026-04-15 | $39.60 10-K · filed 2025-04-15 | |||
| 2024-09-30 | $1.20 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | $1.20 10-Q · filed 2024-08-14 | ||||
| 2023-12-31 | $7487.04 10-K · filed 2025-04-15 | $226.88 10-K · filed 2024-04-01 | |||
| 2023-09-30 | $5.67 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | $5.67 10-Q · filed 2023-08-14 | ||||
| 2022-12-31 | $976.00 10-K · filed 2024-04-01 | $1.22 10-K · filed 2023-03-31 | |||
| 2022-09-30 | $2.27 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | $2.27 10-Q · filed 2022-08-15 | ||||
| 2022-03-31 | $2.31 10-Q · filed 2022-05-16 | ||||
| 2021-12-31 | $3.91 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $3.91 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | $3.91 10-Q · filed 2021-08-23 | ||||
| 2020-12-31 | $0.25 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |